DARPin

Resist resistance fight against cancer arrows out tumor immunotherapy

Biotech

Amgen opts to DARP-out after seeing Molecular Partners data

After a peak at the earliest data for Molecular Partners’ DARPin therapy, Amgen is saying thanks but no thanks on the $550 million partnership.

Annalee Armstrong Apr 26, 2022 4:38pm

Andreas Harstrick MD CMO Molecular Partners

Molecular Partners gets AZ support for lung cancer trial

Apr 11, 2018 9:45am